Illumina Inc. (ILMN) Trading Down 0.8%
Illumina Inc. (NASDAQ:ILMN) shares fell 0.8% during mid-day trading on Monday . The company traded as low as $170.43 and last traded at $170.81, with a volume of 322,984 shares trading hands. The stock had previously closed at $172.21.
A number of research firms have issued reports on ILMN. Canaccord Genuity restated a “hold” rating on shares of Illumina in a research report on Saturday, June 4th. Stifel Nicolaus restated a “buy” rating and set a $160.00 target price (down from $215.00) on shares of Illumina in a research report on Wednesday, May 4th. Citigroup Inc. restated a “buy” rating and set a $175.00 target price (down from $210.00) on shares of Illumina in a research report on Wednesday, May 4th. Morgan Stanley cut their target price on shares of Illumina from $140.00 to $130.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 3rd. Finally, Cantor Fitzgerald restated a “hold” rating and set a $165.00 target price on shares of Illumina in a research report on Wednesday, May 4th. Two research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Illumina has an average rating of “Hold” and a consensus target price of $165.65.
The stock has a market cap of $24.98 billion and a PE ratio of 58.36. The firm has a 50-day moving average of $161.98 and a 200-day moving average of $151.79.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, July 26th. The life sciences company reported $0.86 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.13. During the same quarter in the prior year, the firm earned $0.80 EPS. The firm had revenue of $600 million for the quarter, compared to the consensus estimate of $31.91 million. The company’s revenue was up 11.3% compared to the same quarter last year. On average, equities analysts forecast that Illumina Inc. will post $3.53 earnings per share for the current fiscal year.
In related news, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction on Tuesday, August 23rd. The stock was sold at an average price of $172.99, for a total transaction of $3,459,800.00. Following the completion of the sale, the director now owns 508,061 shares in the company, valued at $87,889,472.39. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Karin Eastham sold 5,000 shares of the company’s stock in a transaction on Wednesday, June 1st. The stock was sold at an average price of $145.35, for a total value of $726,750.00. Following the sale, the director now owns 17,424 shares of the company’s stock, valued at approximately $2,532,578.40. The disclosure for this sale can be found here.
A hedge fund recently raised its stake in Illumina stock. Schwab Charles Investment Management Inc. increased its stake in Illumina Inc. (NASDAQ:ILMN) by 103.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 382,838 shares of the life sciences company’s stock after buying an additional 194,250 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.26% of Illumina worth $73,484,000 at the end of the most recent reporting period.
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.